A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12; Anti-IGF-IR Monoclonal Antibody; IND #100947; NSC # 742460]) in Combination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma: A Groupwide Pilot Study